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Abstract
Metastatic diseases of prostate cancer reveal high expression of K6 integrin and the activation of mitogen-activated protein
kinases (MAP kinase). Therefore, the present study was conducted to examine whether MAP kinase pathway is involved in
the K6 integrin gene expression in androgen-independent prostate cancer cell lines. K6 integrin mRNA expression, the K6
integrin promoter-induced luciferase activities and MAP kinase enzyme activities in androgen-independent LNCaP and PC-3
cell lines were higher than those in androgen-dependent LNCaP. Deletion and mutation analysis showed that Sp1 consensus
sequence at 348 to 343 bp from the transcription start site was necessary for basal promoter activity. Binding of Sp1 to its
consensus sequence in three cell lines was confirmed by electrophoretic mobility shift assays. Sp1 binding to its consensus
sequence, as well as promoter activity and mRNA expression, were found to be inhibited by an inhibitor of MAP kinase
kinase 1 and 2, U0126, in the androgen-independent cell lines. Our results indicate that the proximal Sp1 is necessary for
basal promoter activity of the K6 integrin, suggesting that signal transduction from MAP kinases to activation of Sp1 might
be involved in K6 integrin gene expression in androgen-independent prostate cancer cell lines. ß 2001 Elsevier Science B.V.
All rights reserved.
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1. Introduction
The K6 integrin subunit can couple with L1 and L4
subunits to form receptors for laminin which play a
role in cell invasion [1,2] since anti-K6 integrin anti-
bodies block melanoma cell adhesion to endothelium
[3]. Therefore, changes in expression of K6 integrin
subunits might thus have e¡ects on cancer cell inva-
sion. Expression of K6L1 and K6L4 integrin is di-
rectly related to adhesion to laminin and cell migra-
tion, as well as invasion into matrigel [4,5].
Androgen-dependent LNCaP cells and androgen-in-
dependent PC-3 and DU145 cells express K6L1 [6],
whereas K6L4 integrin is observed in PC-3 and
DU145, but not in LNCaP cells [7]. Androgen-inde-
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pendent cells more readily invade matrigel than their
androgen-dependent counterpart [6]. Moreover,
K6L1 is upregulated in lymph node metastases [8].
Although no direct evidence between androgen-inde-
pendence and metastatic potential in prostate cancer,
these observations suggest that upregulation of the
K6 integrin subunit could be involved in invasion
and metastasis of androgen-independent prostate
carcinomas. High levels of expression of MAP ki-
nases are detected in more advanced, metastatic,
and androgen-independent prostate cancers [9].
Thus, K6 integrin expression seems to be related to
MAP kinases.
Recently, the promoter region of the K6 integrin
gene has been cloned and analyzed [10,11]. Lin et al.
investigated the regulation of the promoter using a
pCAT-promoter vector containing an SV40 en-
hancer. However, their methodology did not seem
to be optimal, and the regulation of the K6 integrin
promoter has yet to be elucidated in detail.
The aim of the present study is to identify cis-act-
ing DNA element and its trans-factors required for
the expression of K6 integrin gene and also to exam-
ine the mechanisms of its regulation in androgen-in-
dependent prostate cancer cells.
2. Materials and methods
2.1. Cell culture
The human prostate cancer cell lines, LNCaP and
PC-3, were purchased from the American Type Cul-
ture Collection (ATCC, Rockville, MD). Androgen-
dependent LNCaP cells (ADL) were cultured in
RPMI-1640 supplemented with 10% FBS. PC-3 cells
were maintained in DMEM/F12 medium containing
10% FBS. Androgen-independent LNCaP cells
(AIDL), which can grow very well in the absence
of androgen, were derived by being maintained in
phenol red free RPMI-1640 medium with 2% char-
coal-stripped FBS for over 2 years as described pre-
viously [12]. In order to inhibit MAP kinase kinases
1 and 2, cells were treated with either 10 WM 1,4-
diamino-2,3-dicyano-1,4 bis[2-aminophenylthio]buta-
diene (U0126: Promega, Madison, WI) or dimethyl
sulfoxide (DMSO) for 48 h. For each experiment,
cells were cultured in phenol red free RPMI-
1640 medium or phenol red free DMEM/F12 me-
dium supplemented with 2% charcoal-stripped
FBS.
2.2. Labeling of cell-surface proteins
Iodination of cell-surface proteins was achieved
with Sonnenberg’s method [13,14]. Brie£y, cells
grown to subcon£uence in 25-cm2 cell culture £asks
were washed three times with phosphate-bu¡ered sa-
line (PBS) and then 400 Wl of PBS, 10 Wl of lactoper-
oxidase (100 Wg), and 10 Wl of Na125I (0.5 mCi) were
added in this order. The iodination reaction was
started by introduction of 25 Wl of freshly prepared
H2O2 solution (0.03% in PBS). After 7.5 min at room
temperature, an additional 10 Wl of lactoperoxidase
(100 Wg) and 25 Wl of H2O2 solution (0.03% in PBS)
were added, and incubation was continued for an-
other 7.5 min. Labeling was stopped by adding ice-
cold PBS.
2.3. Immunoprecipitation
Labeled cells were washed twice with PBS and
lysed with RIPA (radio-immuno-protein assay) bu¡-
er (50 mM Tris^HCl (pH 7.5), 150 mM NaCl, 1 mM
EGTA, 1 mM phenylmethylsulfonyl £uoride
(PMSF), 1% Nonidet P-40 (NP-40), 0.25% sodium
deoxycholate, 1 mM sodium £uoride, 1 mM sodium
orthovanadate, 1 Wg/ml aprotinin, and 1 Wg/ml leu-
peptin). After centrifugation for 10 min, cell lysates
were precleared with Protein A-Sepharose beads
(Sigma, St. Louis, MO). Precleared cell lysates con-
taining 1.5U106 cpm iodinated protein were incu-
bated with monoclonal antibody against human K6
(GoH3, Chemicon Int., Temecula, CA), and L1, L4
(Life Technologies, Rockville, MD) integrin sub-
units. After 1 h incubation at 4‡C, 2 Wg of a⁄nity-
puri¢ed rabbit anti-rat IgG was added to the cell
lysate mixtures. Immune complexes were captured
on Protein A^Sepharose beads and washed three
times with the RIPA bu¡er. The washed beads
were resuspended in sodium dodecyl sulfate (SDS)
sample bu¡er (10 mM Tris^HCl (pH 6.8) 1% SDS,
20% glycerol) and boiled for 5 min (non-reducing
condition). After removal of beads by centrifugation,
the samples were analyzed on SDS^polyacrylamide
gel electrophoresis (PAGE). Autoradiography was
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performed with dried gels, and iodinated integrin
subunits were analyzed.
2.4. Plasmid construction
5P-Deletion constructs (3740Luc, 3182Luc and
3142Luc) were made using convenient restriction
sites within the K6 integrin promoter and the pGL-
3 basic vector containing complementary DNA
(cDNA) encoding the modi¢ed ¢re£y luciferases de-
scribed previously [11]. 3740Luc, 3182Luc and
3142Luc represent 5P-deletion from 3740 bp, 3182
bp, 3142 bp of the K6 integrin promoter in pGL-3
luciferase reporter vector, respectively. Shorter 5P-de-
letion constructs (375Luc, 360Luc and 330Luc)
were prepared by the polymerase chain reaction
(PCR). 375Luc, 360Luc and 330Luc represent 5P-
deletion from 375 bp, 360 bp and 330 bp of the K6
integrin promoter in pGL-3 luciferase reporter vec-
tor, respectively. Upper primers containing a KpnI
site (underlined) were as follows: 5P-GGTACCCA-
AGGAGGGGCGAGAGGTGGGGAG for 375
Luc, 5P-GGTACCGGGTGGGGAGGGGCGGGG-
CCGGCGTC-3P for 360 Luc and 5P-GGTACC-
TCGTCACTTGATAAAACGCCTGC for 335Luc
and the lower primer, 5P-CTTTATGTTTTT-
GGCGTCTTCC-3P, was common. The 3142Luc in
pGL-3 vector was used as a template. All of the PCR
fragments were cloned into the pCR1II vector (In-
vitrogen, Leek, The Netherlands) and the sequences
of PCR products were con¢rmed by sequencing and
subcloning into the pGL-3 basic vector. Several point
mutations of the Sp1 consensus sequences were pre-
pared by using a U.S.E. Mutagenesis kit (Amersham
Pharmacia Biotech, Buckinghamshire, UK) follow-
ing the manufacturer’s protocol. Sp1mLuc represent
mutation of the proximal Sp1 consensus sequence.
Base substitution mutations on the K6 integrin pro-
moter were represented by lowercase boldface letters.
The primers used for mutagenesis were as follows:
5P-GAGGGTGGGAGGatCGcGGCCGGCGTCC
for Sp1mLuc. Mutant clones with the correct diges-
tion pattern were further con¢rmed by sequenc-
ing and then subcloning into the pGL-3 basic vec-
tor.
2.5. Transient transfection and reporter gene activity
assay
Cells were transfected with 1 Wg of reporter plas-
mid and 1 Wg of pRL-TK vector containing cDNA
encoding Renilla luciferase (Promega) for normaliza-
tion, using the TransFast transfection reagent (Prom-
ega). Twenty-four hours after transfection, cells were
washed and lysed. Luciferase activity in cell lysates
was assayed using the Dual-Luciferase Reporter as-
say system (Promega). All values in transfection ex-
periments were normalized for transfection e⁄ciency
by co-transfection with the pRL-TK vector.
2.6. Nuclear extract preparation
Nuclear extracts were prepared as described earlier
[13]. All of the following steps were performed at
4‡C. Brie£y, cells were resuspended in sucrose bu¡er
(0.32 M sucrose, 3 mM CaCl2, 2 mM magnesium
acetate, 0.1 mM EDTA, 10 mM Tris^HCl (pH
8.0), 1 mM dithiothreitol (DTT), 0.5 mM PMSF,
and 0.5% NP-40). The lysate was centrifuged at
500Ug for 5 min to obtain the nuclei pellet, which
were washed with sucrose bu¡er without NP-40. The
nuclei were resuspended in low salt bu¡er (20 mM
Hepes (pH 7.9), 25% glycerol, 0.02 M KCl, 1.5 mM
MgCl2, 0.2 mM EDTA, 0.5 mM DTT, and 0.5 mM
PMSF) followed by addition of high salt bu¡er
(20 mM Hepes (pH 7.9), 25% glycerol, 0.8 M KCl,
1.5 mM MgCl2, 0.2 mM EDTA, 1% NP-40, 0.5 mM
DTT, and 0.5 mM PMSF) for extraction with
incubation for 20 min on a rotary platform. Diluent
(2.5 volumes of 25 mM Hepes (pH 7.6), 25%
glycerol, 0.1 mM EDTA, 0.5 mM DTT, and 0.5
mM PMSF) was added, and the samples were cen-
trifuged at 13 700Ug for 20 min. Five-Wg aliquots of
the supernatant (nuclear extract) were stored at
370‡C.
2.7. Electrophoretic mobility shift assay (EMSA)
The oligonucleotides for probes were synthesized
to span the region between 360 and 333 bp of the
human K6 integrin promoter: wild-type (WT) 5P-
GAGGGTGGGGAGGGGCGGGGCCGGCGTC-
C-3P (Sp1 consensus sequence underlined) and mu-
tated type (mut) 5P-GAGGGTGGGGAGGatC-
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GcGGCCGGCGTCC-3P (substituted bases repre-
sented by lowercase boldface letters). Binding reac-
tions were performed with 32P-labeled double-
stranded oligonucleotides that were incubated with
nuclear extract in binding bu¡er (10 mM Tris^HCl
(pH 7.6), 5% glycerol, 1 mM EDTA, 50 mM NaCl,
1 mM DTT and 0.1 Wg/ml poly(dI-dC)). For oligo-
nucleotide competition analysis, 25- or 100-fold mo-
lar excesses of unlabeled oligonucleotides were also
added to the mixture. After incubation at 25‡C for
30 min, mixtures were analyzed on 4% nondenatur-
ing polyacrylamide gels. For antibody super shift
assays, 1 Wl of anti-Sp1, -Sp2, -Sp3 or -Sp4 antibod-
ies (Santa Cruz Biotechnology, Santa Cruz, CA) was
added to the mixture prior to the addition of the
probe with incubation at 4‡C for 1 h. Protein^
DNA complexes were fractionated on 4% nondena-
turing polyacrylamide gels in 0.5UTris-Borate-
EDTA bu¡er at 4‡C and visualized by autoradiog-
raphy.
2.8. Ribonuclease protection assay
Total RNA was isolated from U0126 or vehicle-
treated cells using the Ultraspec RNA isolation sys-
tem (Biotecx Laboratories, Houston, TX). A 613 bp
K6 integrin subunit cDNA fragment was obtained by
PCR with the following primers: 5P-TGGTTT-
CCTTTCGGCTCTCC-3P and 5P-GCCACCTGAC-
GCTCTTTTTG-3P. Also, a 553 bp human L-actin
cDNA fragment was ampli¢ed by PCR with the
primers; 5P-AGAAATCTGGCACCACACC-3P and
5P-AGGAAGGAAGGCTGGAAGAG-3P. The am-
pli¢ed cDNA fragments were cloned into pCR1II
vectors. Digestion of L-actin cDNA with MspI pro-
duces 255 bp of linearized L-actin cDNA fragments
for in vitro transcription. K6 integrin cDNA was
linearized with EcoRV. Antisense RNAs for target
mRNAs were synthesized from linearized DNA, us-
ing SP6 RNA polymerase (Promega) in the presence
of [32P]uridine triphosphate (3000 Ci/mmol). After
the reaction, DNA templates were digested with de-
oxyribonuclease I and the antisense RNAs were pu-
ri¢ed by phenol^chloroform extraction. Hybridiza-
tion and the detection of protected bands were
performed as described previously [15].
2.9. MAP kinase enzyme assay
Cells were treated with either 10 WM U0126 or
DMSO for 48 h, then lysed in 10 mM Tris^HCl,
150 mM NaCl, 2 mM EGTA, 2 mM DTT, 1 mM
orthovanadate, 1 mM PMSF, 10 Wg/ml leupeptin, 10
Wg/ml aprotinin, 0.1% Triton X, pH 7.4. Cell debris
was omitted by centrifugation at 25 000Ug for 20
min. MAP kinase enzyme activity in the supernatant
was determined by p42/p44 MAP kinase enzyme as-
say system (Amersham Pharmacia Biotech). The de-
terminations were performed in duplications in three
di¡erent preparation, according to the manufactur-
er’s instruction.
The data are presented as mean þ S.E.M. values
from three independent experiments. In statistical
analysis unpaired t-tests were used. P values less
than 0.05 were de¢ned as statistically signi¢cant.
3. Results
At ¢rst, the expression of K6, L1, L4 integrin in
three cell lines was demonstrated. As shown in Fig.
1, K6 (lanes 1, 4, 7) and L1 integrin (lanes 3, 6, 9)
expressions were observed in all three cell lines.
L4 expression was evident in PC-3 (lanes 7 and 8),
whereas no band for L4 integrin in AIDL (lane 5)
Fig. 1. Expression of K6, L1, and L4 integrin subunits in pros-
tate cancer cell lines. Cell-surface proteins (ADL, lanes 1^3;
AIDL, lanes 4^6; PC-3, lanes 7^9) were labeled with Na125I,
immunoprecipitated with anti-K6 (lanes 1,4,7), L4 (lanes 2,5,8),
and L1 (lanes 3,6,9) integrin subunit antibodies.
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and only faint band was seen in ADL (lanes 1 and 2).
These results are consistent with the previous ¢nd-
ings [6,7].
In order to decide the minimal promoter region of
the K6 integrin and to compare luciferase activities
among ADL, AIDL and PC-3 cells, these cells were
transiently transfected with a series of K6 integrin
promoter deletion constructs in luciferase-containing
plasmids (Luc-plasmids: Fig. 2A). Analysis of the
respective luciferase activity revealed notable basal
activity with the 3740 pGL-3 construct (3740Luc)
in all three lines. The luciferase activity in PC-3 was
approximately 4-fold and in AIDL was 2-fold that in
ADL cells. While shorter constructs (3182Luc,
3142Luc, 375Luc and 360Luc) demonstrated com-
parable constitutive activity to the longest reporter
gene plasmid, the 330Luc showed loss of basal tran-
scriptional activity. These ¢ndings indicate that the
minimal promoter activity, containing an Sp1 con-
sensus sequence, is located between 360 and 330
bp with respect to the transcription initiation site
of the K6 integrin promoter and that androgen-inde-
pendent cells show higher promoter activities than
their androgen-dependent counterpart. Then, a base
substitutions approach was adopted to inquire the
contribution of Sp1 consensus sequences to the ex-
pression of K6 integrin. A mutated K6 integrin Luc-
plasmid (Sp1mLuc: Fig. 2B) was generated from
3142Luc, and activities were measured after trans-
fection into the three prostate cancer cell lines. As
shown in Fig. 3, Sp1mLuc was associated with great
reduction in K6 integrin promoter activity. These re-
sults suggest that the proximal Sp1 consensus se-
quence in the 348 to 343 region is essential for basal
promoter activity. These ¢ndings with mutation con-
structs were consistent with the data obtained from
the 5P-deletion experiments (Fig. 2A,B).
As shown in Fig. 3, we examined the contribution
of the proximal Sp1 consensus sequence (348 to 343
bp) to the promoter activity using electrophoretic
mobility shift assays (EMSAs). The double-stranded
oligonucleotide probe contains the proximal Sp1
consensus sequence in the K6 integrin promoter. Spe-
ci¢c DNA^protein complexes (indicated by arrows)
were observed with both ADL and AIDL cells (Fig.
3A,B). When anti-Sp1 antibody was added to EMSA
reactions, the band indicated by the arrow super-
shifted to a higher molecular mass (arrowhead).
When anti-Sp3 antibody was added, the band indi-
cated by the asterisks disappeared without super-
shifted band. This suggests that the bands indicated
by the asterisks might represent Sp3 binding to the
proximal Sp1 consensus sequence. Anti-Sp2 and Sp4
antibodies had no e¡ects on bands in ADL and
AIDL cells (Fig. 3A,B). In the PC-3 nuclear extract,
only one DNA^protein complex was seen and a
supershifted band was only observed with addition
of anti-Sp1 antibody (Fig. 3C). These data suggest
that Sp1 and/or Sp3 in ADL and AIDL cells, and
Fig. 2. Deletion and mutation analysis in the K6 integrin pro-
moter in human prostate cell lines. (A) Deletion constructs and
promoter activities of human K6 integrin. Deletion constructs
containing luciferase (Luc-plasmids) were transiently transfected
into ADL (open column), AIDL (shaded column), PC-3 (closed
column). The diagram on the left is a map of the series of 5P-
deletion K6 integrin promoters in Luc-plasmids. Transcription
factor binding sites are also shown. (B) E¡ects of base-substitu-
tion mutations in the Sp1 consensus sequences in the K6 integ-
rin promoter. Luc-plasmids containing various base-substitution
mutations in the proximal Sp1 consensus sequences in the K6
integrin promoter were generated. The mutation construct was
transiently transfected into ADL (open column), AIDL (shaded
column), PC-3 (closed column). The diagram on the left shows
the structure of each base-substitution mutant with substituted
bases represented by lowercase boldface letters. Normalized lu-
ciferase activities are shown on the right. The data are mean þ
S.E.M. values (n = 3).
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only Sp1 in PC-3 could play critical roles in the tran-
scriptional activity of the K6 integrin gene.
From the data described above, Sp1 is the key
transcription factor in K6 integrin gene expression.
DNA binding activity could be one of the mecha-
nisms of regulation of Sp1-dependent transcription.
Next we examined whether the Sp1 binding activity
in an androgen-independent cell is higher than in an
androgen-dependent counterpart. Equal amounts of
nuclear extracts from ADL and AIDL were utilized
for EMSAs. As shown in Fig. 4, AIDL showed high-
er DNA^Sp1 binding activity than ADL, suggesting
constitutive upregulation with androgen independ-
ence.
Earlier studies [8,9] suggest that the MAP kinase
pathway might be involved in K6 integrin gene ex-
pression in advanced prostatic cancer. To address
this question, we examined MAP kinase enzyme ac-
tivities and selected U0126, which is a novel inhibitor
of the MAP kinase kinases 1 and 2 [16]. At ¢rst, to
examine the e¡ects of U0126 in androgen-independ-
ent cell lines, we investigated change in the MAP
kinase enzyme activities. As shown in Fig. 5A,
Fig. 3. Binding of Sp1 transcription factor to the proximal Sp1 consensus sequence in the K6 integrin promoter. Five-Wg nuclear ex-
tracts (NE) from ADL (A), AIDL (B), PC-3 (C) cells were used in all EMSAs. The fragment for 360 to 332 bp of the K6 integrin
promoter containing the proximal Sp1 consensus sequence was used as a wild-type probe (WT) in the absence or presence of a 25- or
100-fold molar excess of the unlabeled wild-type double-stranded oligonucleotides. Mutation probes (mut) were employed in A and C.
For supershift assay, anti-Sp1, -Sp2, -Sp3 or -Sp4 antibodies were applied. Speci¢c bands are indicated by the arrows and that super-
shifted by Sp1 antibody by arrowheads in A^C. Bands including Sp3 are indicated by asterisks in A and B.
Fig. 4. Di¡erence in Sp1 binding to the proximal Sp1 consensus
sequence between ADL and AIDL cells. Five Wg NE from
ADL and AIDL cells were used in EMSAs with the same
probe as in Fig. 3. The arrowhead represents the band super-
shifted by the Sp1 antibody. Bands including Sp3 are indicated
by the asterisk.
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MAP kinase enzyme activities in AIDL and PC-3 cell
lines were signi¢cantly higher than those in andro-
gen-dependent LNCaP (P6 0.05 and P6 0.01, re-
spectively). The enzyme activities in androgen-inde-
pendent cell line signi¢cantly decreased with U0126
treatment (both P6 0.01). The e¡ects of U0126 on
K6 integrin promoter activities were investigated by
ribonuclease protection and luciferase assays. U0126
inhibited K6 integrin transcription in AIDL and PC-
3 (Fig. 5B). Consistent with these ¢ndings, the pro-
moter activities in U0126-treated cells were reduced
by approximately half in both AIDL (Fig. 6A) and
PC-3 (Fig. 6B). However, if the proximal Sp1 con-
sensus sequence was deleted or mutated (330Luc or
Sp1mLuc), the downregulation by U0126 and basal
promoter activity were abrogated in both AIDL
(Fig. 6A) and PC-3 (Fig. 6B). These results suggest
that the proximal Sp1 consensus sequence is required
for U0126-sensitive promoter activity.
Finally, to investigate if the Sp1 binding activity is
altered by U0126, EMSAs were performed with nu-
clear extracts from AIDL and PC-3 treated with ei-
ther U0126 or vehicle. The intensity of Sp1 binding
in the nuclear extract from the U0126-treated AIDL
was decreased by approximately two-thirds, and
greater reduction was observed with U0126-treated
PC-3 (Fig. 7), suggesting that the MAP kinase path-
way might be, at least in part, involved in the regu-
lation of Sp1 binding to its proximal consensus se-
quence in the K6 integrin promoter.
4. Discussion
Our working hypothesis is that MAP kinase path-
way is involved in the K6 integrin gene expression in
androgen-independent prostate cancer cell lines. The
present study demonstrates that the proximal Sp1
consensus sequence is essential for basal promoter
activity of K6 integrin in androgen-independent pros-
tate cancer cell lines. This basal activity of K6 integ-
rin promoter is sustained by MAP kinases because
U0126, a MAP kinase kinase 1 and 2 inhibitor, sup-
pressed both the K6 integrin basal promoter activity
and its mRNA expression. This inhibitory e¡ect was
totally abolished when the proximal Sp1 consensus
sequence was mutated. Sp1 binding activity to its
consensus sequence was also reduced by U0126.
These data could indicate that the MAP kinase path-
way might be involved in the K6 integrin gene ex-
pression via transcription factor, Sp1. It is well
known that the MAP kinase pathway is related to
gene expressions such as serum response element
(SRE) [17], interferon-stimulated response element
(ISRE) and Q-interferon activation site (GAS)
[18,19]. However, these consensus sequences do not
exist on the K6 integrin promoter which was used in
the present study.
Evidence has been reported that the stimulation of
cell proliferation leads to activation of Sp1 transcrip-
tion ability. Binding of Sp1 to the dihydrofolate re-
Fig. 5. MAP kinase enzyme activities and K6 integrin mRNA
expression in ADL, AIDL, PC-3 cells. (A) MAP kinase activ-
ities and its inhibition by U0126. Cells were treated with 10
mM U0126 (open column) or vehicle (closed column) for 48 h.
Bars represent mean þ S.E.M. (n = 3). Signi¢cant di¡erence be-
tween the MAP kinase activity for ADL and the corresponding
values for androgen-independent counterparts obtained by the
unpaired t-test are indicated by *P6 0.05, **P6 0.01,
2P6 0.01, compared with MAP kinase in cells treated with
U0126. (B) U0126 inhibition of K6 integrin mRNA expression.
Cells were treated with 10 WM U0126 or vehicle for 48 h. Fifty
Wg total RNA from either U0126 or vehicle-treated cells were
applied in a ribonuclease protection assay. The bands hybridiz-
ing with 32P-labeled antisense of K6 integrin or L-actin probes
are indicated by arrows.
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ductase promoter has been found to be elevated in
serum-stimulated CHO cells [20]. Activation of the
MAP kinase module by platelet-derived growth fac-
tor B resulted in an increase of the vascular endothe-
lial cell growth factor (VEGF) promoting activity via
a Sp1 consensus sequence [21]. Milanini et al. also
described that introduction of constitutively active
Ras into ¢broblast resulted in increasing Sp1 binding
and the promoter activity in VEGF [22]. These ¢nd-
ings might support our results that Sp1 binding may
be upregulated through the MAP kinase pathway in
K6 integrin promoter. Phosphorylation of the car-
boxyl terminus of Sp1 controls its transcription ac-
tivity which is regulated in the cell cycle [23]. U0126
might have some sort of e¡ect on the Sp1 phosphor-
ylation state although it has yet to be assessed.
Therefore, our results indirectly showed that Sp1
could be the downstream target of the MAP kinase
signal transduction pathway in the K6 integrin gene
expression in androgen-independent prostate cancer
cells.
Sp1 is also known to interact with retinoblastoma
gene product (Rb). In this case, Rb can modulate
Sp1-mediated transactivation through the retinoblas-
toma control element (RCE) motif, possibly through
release of Sp1 from a negative regulator of transcrip-
tion [24,25]. Moreover, Rb is directly associated with
Sp1 and this association increases Sp1-mediated
transcription of the dihydrofolate reductase pro-
moter [26]. In the case of the K6 integrin promoter,
the promoter sequence used in the present study does
not have any RCE motives; moreover, anti-Rb anti-
body produces no supershift of radiolabeled Sp1
consensus oligonucleotides in EMSAs (data not
shown). Therefore, there is little possibility that Rb
might modify K6 integrin gene expression via its
binding to Sp1.
Fig. 6. E¡ects of U0126 on K6 integrin promoter activity. K6 integrin promoter constructs (3740Luc, 360Luc, 330Luc and
Sp1mLuc) were transfected into AIDL (A) or PC-3 (B), followed by incubation with medium containing 10 WM U0126 (open column)
or vehicle (closed column) for 48 h and then luciferase activities were measured. The data are mean þ S.E.M. values (n = 3). 2P6 0.01,
compared with luciferase activities in cells treated with U0126.
Fig. 7. U0126 inhibition of Sp1 binding to its proximal consen-
sus sequence in the K6 integrin promoter. Nuclear extracts
(NE) were extracted from AIDL or PC-3 cells incubated with
or without U0126 (10 WM) for 48 h. EMSAs were performed
with 5 Wg of NE and the same oligonucleotide probe as de-
scribed in Fig. 3. The arrows and an arrowhead indicate a spe-
ci¢c and non-speci¢c band, respectively.
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Growth factors such as epidermal growth factor,
transforming growth factor K, insulin-like growth
factor, interleukin 6, keratinocyte growth factor, oth-
er ¢broblast growth factor family members are ex-
pressed in androgen-independent prostate cancers
[27]. Elevated levels of MAP kinase activity in an-
drogen-independent prostate cancer cells have been
demonstrated in the present study. The results sug-
gest that growth factors autocrined result in activa-
tion of the MAP kinase pathway. Actually elevated
levels of activated MAP kinase are observed in ad-
vanced and androgen-independent prostate cancers
[19]. Therefore, these ¢ndings are in line with the
hypothesis in the present study. Further study is
now required to elucidate how the signal transduc-
tion pathway through MAP kinases regulates the in-
crease of Sp1 binding to its consensus sequence.
In conclusion, Sp1 is necessary for basal promoter
activity of the K6 integrin, and the binding activity
might mediate its transcriptional regulation with a
contribution of the MAP kinase pathway in andro-
gen-independent prostate cancer cells.
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